Business Context and Reporting Period
Company: Inmed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2026
Reporting Period: Third quarter of fiscal year 2026, ended March 31, 2026.
Event: Regulation FD Disclosure regarding the reporting of financial results for the period mentioned above.
Key Financial Metrics
The provided filing text serves as a cover document for the disclosure of financial results but does not contain the specific numerical data. The following metrics are not present in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing states that detailed information is contained in Exhibit 99.1 (News release), which is not included in the provided input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that financial results for the third quarter of fiscal 2026 were reported.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that the President & CEO, Eric A Adams, authorized the report on May 6, 2026. No specific commentary, guidance, or outlook is included in the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this document.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (News release dated May 6, 2026) to obtain the actual financial figures for the third quarter of fiscal 2026.
- Verify the specific revenue, net loss, and cash burn rates reported in the referenced news release.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full news release.
- Confirm the company's cash position and runway as of March 31, 2026, which are not listed in this summary document.